Compare Hyatt Hotels Corporation (H) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Heron Therapeutics Inc — how do they compare? Hyatt Hotels Corporation trades at $159.3 (market cap $14.81B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Hyatt Hotels Corporation is far larger — about 200× Heron Therapeutics Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Heron Therapeutics Inc for 35 Days on average.
| H | HRTX | |
|---|---|---|
Market Cap | $14.81B | $74.04M |
Volume | 588,239 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $1.49 |
52-Week Low | $135.42 | $0.27 |
Typical Hold Time | 148 Days | 35 Days |
Enterprise Value | $18.71B | $180.78M |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $159.43, up 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, though Q3 2026 results are pending. Revenue grew to $7.10 billion in 2025, but net income was negative $52 million, reflecting margin pressure. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid mixed financial performance.
The outlook for Hyatt is cautiously optimistic, supported by analyst consensus and strategic partnerships, but high valuation multiples and inconsistent profitability pose risks. Upside potential exists if operational improvements and fee growth materialize, yet investors face headwinds from debt levels and competitive pressures in the hospitality sector.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
